Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490225 | 1.00 | CA1 (0.55) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL685083 | 0.99 | CA1 (0.57) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL3986887 | 0.90 | ALDH1A1 (0.59) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL3911160 | 0.90 | ALDH3A1 (0.59) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL3986882 | 0.90 | ALDH1A1 (0.59) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL3911162 | 0.90 | ALDH3A1 (0.59) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL3911113 | 0.81 | KDR (0.48) | ALDH1A1KDRRETPDGFRBFLT3 | |
| SCHEMBL3911110 | 0.81 | KDR (0.48) | ALDH1A1KDRRETPDGFRBFLT3 | |
| SCHEMBL5817331 | 0.76 | CA1 (0.50) | CA1CA2ALDH3A1ALDH1A1BCHE | |
| SCHEMBL5817327 | 0.76 | CA1 (0.50) | CA1CA2ALDH3A1ALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106039-B2 | Metal complex phosphatidyl-inositol-3-kinase inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-01-31 | — | — | US | disclosed |
| US-7671046-B2 | Metal complex protein kinase inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNYSLVANIA (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009134825-A1 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS | THE TRUSTEES OF UNIVERSITY OF PENNSYLVANIA (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275547-A1 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-11-05 | — | — | US | disclosed |
| US-7488817-B2 | Metal complex protein kinase inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080275019-A1 | METAL COMPLEX PROTEIN KINASE INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1301507-B1 | MANNICH BASE PRODRUGS OF 3 - (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | SUGEN INC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1294711-B8 | 1-(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1294711-B8 | 1-(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1294711-B8 | 1-(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6451838-B1 | ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6451838-B1 | ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-09-17 | — | — | US | disclosed |
| WO-2001090104-A3 | -(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | UPJOHN CO (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001090104-A3 | -(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | UPJOHN CO (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020035140-A1 | 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | disclosed |
| US-20020035140-A1 | 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | disclosed |
| US-20020035140-A1 | 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | disclosed |
| WO-2001090104-A2 | -(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090104-A2 | -(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090104-A2 | -(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275547-A1 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS | PI4KA, PI4KB, PIP4K2B | CA1 1262/4885CA2 569/4885ALDH3A1 3201/4885 |
| US-20080275019-A1 | METAL COMPLEX PROTEIN KINASE INHIBITORS | CAMK1, CAMK1G, CAMKK2 | CA1 2528/4885CA2 1002/4885ALDH3A1 3829/4885 |
| US-20020035140-A1 | 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PKLR, DMPK, PHKG1 | CA1 4881/4885CA2 4444/4885ALDH3A1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.